Omnitrope’s Low Switch Rate Due To Inferior Delivery Device - Express Scripts

A delivery device of Sandoz's follow-on recombinant human growth hormone Omnitrope that "doesn't cut it" has led to a low generic substitution rate that will not predict the substitutability of future generic biologics, Express Scripts Chief Medical Officer Steven Miller said at a Food and Drug Law Institute conference Nov. 15